Top Markets
Coin of the day
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Pozycja w akcjach #40868
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Cena akcji
$0.02765
Ostatnia synchronizacja: 2024-12-23
Kapitalizacja rynkowa
$69.04K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Histogen Inc. (HSTO)

Kategoria

EPS dla Histogen Inc. (HSTO)
EPS na dzień September 2023 TTM: $-3.13
Według najnowszych raportów finansowych i ceny akcji firmy Histogen Inc., obecny EPS (TTM) wynosi $-3.13. Na koniec roku 2021 firma miała EPS w wysokości $-7.51, wzrost w porównaniu do do EPS z roku 2020, który wynosił $-41.60.
Historia EPS dla Histogen Inc. od 2011 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
2026 (TTM) $-3.13 -9.54%
2022 $-3.46 -53.93%
2021 $-7.51 -81.95%
2020 $-41.60 728.69%
2019 $-5.02 -95.77%
2018 $-118.60 -2.56%
2017 $-121.71 -53.64%
2016 $-262.55 20,096.15%
2015 $-1.30 -9.72%
2014 $-1.44 -32.08%
2013 $-2.12 -98.88%
2012 $-190.00 -26.92%
2011 $-260.00 0.00%
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$17.32 -653.35%
US
$27.74 -986.26%
NL
- -
CH
- -
KR
$13.70 -537.70%
BE